Stockreport

Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma

Chimerix, Inc.  (CMRX) 
Last chimerix, inc. earnings: 2/25 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.chimerix.com/investor-relations
PDF DURHAM, N.C., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve [Read more]